Strict control of atherogenic cholesterol and cardiovascular disease prevention Carlos Guijarro;

Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey Carlos Guijarro; Fernando Civeira; José López-Miranda; Luis Masana; Juan Pedro-Botet; Xavier Pintó; Pedro Valdivielso; José María Mostaza;

Efficacy and safety of PCSK9 inhibitors in real life Antón González-Guerrero; Eugenia Navarrete-Rouco; David Benaiges; Eva Giralt-Steinhauer; Lidia Marcos; Anna Oliveras; Lluis Recasens; Juan Pedro-Botet;